A
A
    Global websites
    Local websites
    language header world map

    Post-Trial Access

    At argenx, we believe participation in a clinical trial within a controlled setting is the most appropriate way to access investigational products.

    In our clinical trials, the information shared with participants and health care professionals clearly states the length of the study and how long participants will be treated with the investigational product.

    However, argenx recognizes that during a clinical trial, some participants may feel they have benefited from the investigational product, yet they do not have access to the product after their participation in the trial has ended because it is not yet approved or commercially available in their country. Under specific circumstances, if an individual request is received from a clinical trial investigator, argenx may provide access to the investigational product post-trial but before it is approved or commercially available.

    argenx will evaluate each request on a case-by-case basis, weighing all of the following criteria:

      • The participant has a serious or immediately life-threatening condition, has no other suitable treatment options available and does not qualify for another ongoing clinical trial;
      • The medicine is not yet approved or commercially available for the indication or is not available by other means in the country where the trial was conducted;
      • The request for Post-Trial Access was made by the clinical trial investigator in writing;
      • The participant was part of a clinical trial in which the medicine was administered immediately following the end of active clinical trial participation;
      • The risks and benefits of using the medicine in the particular disease or condition indicate a favourable risk-benefit assessment for the individual based on the investigator’s evaluation of the participant’s response to the intervention, in consultation with argenx;
      • argenx has an adequate supply of product to provide to the patient and, if applicable, to support ongoing clinical trials that are critical to getting the new treatment approved and thereby reach the broadest possible patient population;
      • argenx will only consider a PTA request in a country where there is a Bonafide intent for commercialization after a PTA;
      • A request for PTA to a product is in compliance with all local laws and regulations and access within the PTA is temporary until the product is commercially available.
      Grants Image

      Post-trial responsibilities are shared among all stakeholders: sponsor, investigator, health care provider, health care system and the participant. If continuing medical care and/or infrastructure are necessary for the appropriate provision of the investigational product post-trial, all stakeholders must work together to ensure their provision.

      argenx reserves the right to provide access either through a larger program or on an individual patient basis in countries where argenx intends to seek regulatory approval; otherwise, the preferred approach will be named (or individual) patient programs.

      argenx will periodically re-evaluate its post-trial access responsibilities during the course of the participant’s post-trial access. If new information becomes known about the investigational product, the ongoing health of the individual and/or market availability of the product or alternative therapies, post-trial access may be terminated with clear communication to investigator and patient of rationale.